Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)’s share price traded up 9.3% during trading on Wednesday . The stock traded as high as $1.45 and last traded at $1.41. 446,007 shares were traded during trading, a decline of 46% from the average session volume of 831,322 shares. The stock had previously closed at $1.29.

The company has a debt-to-equity ratio of 1.18, a current ratio of 2.12 and a quick ratio of 1.86. The stock has a market cap of $17.43 million, a P/E ratio of -1.78 and a beta of 0.94.

Titan Pharmaceuticals (NASDAQ:TTNP) last announced its quarterly earnings data on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). Titan Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 311.18%. The firm had revenue of $0.95 million for the quarter. As a group, equities analysts expect that Titan Pharmaceuticals, Inc. will post -0.68 EPS for the current year.

An institutional investor recently raised its position in Titan Pharmaceuticals stock. Vanguard Group Inc raised its holdings in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) by 12.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 432,337 shares of the specialty pharmaceutical company’s stock after purchasing an additional 48,760 shares during the quarter. Vanguard Group Inc owned 0.55% of Titan Pharmaceuticals worth $90,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 5.08% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2019/06/12/titan-pharmaceuticals-nasdaqttnp-trading-9-3-higher.html.

Titan Pharmaceuticals Company Profile (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

Read More: What is a Futures Contract?

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.